Cerevasc has today announced that findings from a clinical study examining the use of its eShunt system to treat communicating hydrocephalus were recently presented at the 2023 European Society of Minimally Invasive Neurological Therapy (ESMINT) congress (4–6 September, Marseille, France).
Trial data reporting the investigational use of the eShunt system in patients with hydrocephalus secondary to subarachnoid haemorrhage were delivered by Ivan Lylyk (Clínica La Sagrada Familia, Buenos Aires, Argentina)—one of the lead investigators for a study that represents the first ever treatment with the eShunt system and the world’s first endovascular treatment of communicating hydrocephalus, according to Cerevasc.
The presentation, titled “Early experience with the eShunt implant in the management of aneurysmal subarachnoid haemorrhage intractable hydrocephalus”, described the short-term impact of the eShunt system in patients with persistent communicating hydrocephalus and elevated intracranial pressure in lieu of the invasive, surgical placement of a conventional ventriculoperitoneal shunt.
“We are excited by the initial data demonstrating the potential to provide patients a minimally invasive treatment for communicating hydrocephalus,” said Pedro Lylyk (Clínica La Sagrada Familia, Buenos Aires, Argentina), who is leading the study. “Transformational innovation in the management of hydrocephalus is long overdue. These results provide confidence that it may finally be on the horizon.”
“We are thrilled by the results reported, and grateful to Dr Lylyk and the team from Clínica La Sagrada Familia for presenting their clinical experience with the eShunt system to the physician community,” stated Cerevasc president and CEO Dan Levangie. “The data presented at ESMINT bolster our confidence in the potential of the company’s minimally invasive treatment of hydrocephalus as we transition to the pivotal clinical trial in early 2024.”
